Sunshine Data Could Fast-Track False Claims Act Cases – U.S. Prosecutors
Executive Summary
Sunshine Act penalties are relatively small but the payment disclosures could provide ammo and shortcuts for investigations into the more costly False Claims Act cases, U.S. attorneys say. On the flip side, disclosure may lead to better behavior.
You may also be interested in...
Under DOJ’s Microscope: Teva Is Latest Company To Face Government Probe
AstraZeneca, Merck, Novartis and Sanofi are also under investigation for potential health care fraud.
Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.